ABT 110

Drug Profile

ABT 110

Alternative Names: ABT-110; HU αD11; Hu-alpha-D11; HuAlphaD11; PG-110

Latest Information Update: 05 Feb 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lay Line Genomics
  • Developer AbbVie
  • Class Analgesics; Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Nerve growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Back pain; Pain

Most Recent Events

  • 26 Jan 2013 Discontinued - Phase-II for Pain in Argentina (IV)
  • 26 Jan 2013 Discontinued - Phase-II for Pain in Australia (IV)
  • 26 Jan 2013 Discontinued - Phase-II for Pain in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top